cantuzumab
labetuzumab
patritumab
antinucleotide
milatuzumab
scintimammography
pertuzumab
farletuzumab
votumumab
mammothermography
oncoimmunotherapy
tasonermin
neoplastic cell
teprotumumab
mosunetuzumab
adenoma
igovomab
cedelizumab
arcitumomab
siltuximab
antithyroglobulin
robatumumab
immunotherapy
pancytokeratin
immunocytokine
-tum-
cancer cell
cergutuzumab
cytotoxic reaction
soravtansine
tisotumab vedotin
apolizumab
immunoblastoma
citatuzumab bogatox
boob cancer
amivantamab
iratumumab
intrabody
oophoroma
immunocytoma
oregovomab
amazia
antisynthetase
malignin
perimammary
agonistic monoclonal antibody
olendalizumab
etaracizumab
immunobinding